STRATA SKIN SCIENCES, INC.

SSKN

CIK 0001051514 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$9M
↓-3.0% -$284Kvs FY2024 (Q4)
Operating Income
$5M
↑+7.0% +$311Kvs FY2024 (Q4)
Net Income
$4M
↑+8.5% +$330Kvs FY2024 (Q4)
Gross Profit
$6M
↓-4.0% -$231Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
15/100
  • Profitability
    0ROIC -19.3% (10% = solid, 20%+ = moat)
  • Liquidity
    4Current Ratio 0.58 (above 1.5 = solid)
  • Leverage
    0D/E 5.28 (under 0.5 = conservative)
  • Efficiency
    57Asset Turnover 0.94x (1.0+ = capital-efficient)
  • Growth
    7Revenue YoY -3.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    20Op Margin -16.9% · trend -1.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$2M
investment in PP&E
Stock-based comp (TTM)
$643K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$31M
everything owned
Total liabilities
$28M
everything owed
Stockholders' equity
$3M
shareholder claim
Net debt
$7M
LT debt minus cash

Recent performance · 63 quarters

Revenue↓-3.0% -$284K
$9M
Net Income↑+21.8% +$452K
$-2M
Free Cash Flow↓-256.8% -$511K
$-312K
Operating Margin↑+1.3pts
-16.9%

Drill down